Septerna (SEPN) Income from Continuing Operations (2023 - 2026)
Septerna (SEPN) recorded quarterly Income from Continuing Operations of 8637000.0 in Q1 2026, up 19.57% quarter-over-quarter from 10738000.0 in Q4 2025, and up 59.78% on a YoY basis from 5405455.69 in Q1 2025.
Septerna (SEPN) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Septerna's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 8637000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 59.78% year-over-year to 8637000.0; the TTM figure through Mar 2026 stood at 36040000.0 (up 54.57% YoY), while the FY2025 annual figure was 48879000.0, up 31.92% from the prior year.
- Income from Continuing Operations was 8637000.0 for Q1 2026 at Septerna, up from 10738000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8173000.0 in Q3 2025 to a low of 24838000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 14437818.18 across 4 years, with a median of 16659000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 87.51% in 2024, then soared 139.82% in 2025.
- A 4-year view of Income from Continuing Operations shows it stood at 18153000.0 in 2023, then slipped by 13.85% to 20668000.0 in 2024, then jumped by 48.05% to 10738000.0 in 2025, then rose by 19.57% to 8637000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8637000.0 (Q1 2026), 10738000.0 (Q4 2025), and 8173000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Septerna | 1.37 Bn | 1.37 Bn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.74 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.67 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.66 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -18.15 Mn |
| Sep 30, 2023 | -10.95 Mn |